Methotrexat Kelix Bio

Methotrexate, the active ingredient in Methotrexat Kelix Bio, is a folate antagonist presented as a unknown/unknown for intramuscular, intrathecal, and intravenous use. It treats rheumatoid arthritis, psoriasis, acute lymphoblastic leukemia, non‑Hodgkin lymphoma, and gestational trophoblastic disease in appropriate patients.

GNH USA supplies Methotrexat Kelix Bio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Methotrexate acts as a folate pathway inhibitor and is employed in several immune‑mediated and oncologic conditions. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: diminishes skin cell proliferation and improves lesions. - Acute lymphoblastic leukemia: interferes with malignant cell replication to achieve remission. - Non‑Hodgkin lymphoma: impedes tumor growth and supports remission. - Gestational trophoblastic disease: halts abnormal trophoblastic tissue proliferation.

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea and vomiting. - Fatigue or malaise. - Mucositis or oral ulceration. - Alopecia (hair loss). - Elevated liver enzymes. - Mild cytopenias (low blood counts).

Serious or Rare Side Effects: - Severe hepatotoxicity or liver fibrosis. - Pulmonary fibrosis or interstitial pneumonitis. - Life‑threatening bone marrow suppression. - Acute renal failure. - Severe cutaneous reactions (e.g., Stevens‑Johnson syndrome). - Opportunistic infections due to profound immunosuppression.

Methotrexate requires careful monitoring and specific safety measures. - Pregnancy: contraindicated (Category X); avoid use in women of childbearing potential. - Renal function: assess baseline and monitor; dose adjustment may be needed. - Liver function: regular enzyme testing is essential to detect hepatotoxicity. - Hematologic status: monitor complete blood counts for cytopenias. - Infection risk: postpone therapy in active infections and monitor for opportunistic infections. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several drug classes that can modify its safety or efficacy.

Major Interactions (Avoid): - Nonsteroidal anti‑inflammatory drugs (NSAIDs): increase renal toxicity. - Aminoglycoside antibiotics: enhance nephrotoxic risk. - Live vaccines: may cause severe infection. - Trimethoprim‑sulfamethoxazole: additive bone‑marrow suppression. - Phenytoin: may reduce methotrexate plasma levels.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may affect absorption. - Sulfonamides: increase overall toxicity. - Penicillins: can raise methotrexate concentrations. - Alcohol: may exacerbate hepatotoxicity. - Folic acid supplements: may diminish therapeutic effect.